Literature DB >> 17580654

The innovation value chain.

Morten T Hansen1, Julian Birkinshaw.   

Abstract

The challenges of coming up with fresh ideas and realizing profits from them are different for every company. One firm may excel at finding good ideas but may have weak systems for bringing them to market. Another organization may have a terrific process for funding and rolling out new products and services but a shortage of concepts to develop. In this article, Hansen and Birkinshaw caution executives against using the latest and greatest innovation approaches and tools without understanding the unique deficiencies in their companies' innovation systems. They offer a framework for evaluating innovation performance: the innovation value chain. It comprises the three main phases of innovation (idea generation, conversion, and diffusion) as well as the critical activities performed during those phases (looking for ideas inside your unit; looking for them in other units; looking for them externally; selecting ideas; funding them; and promoting and spreading ideas companywide). Using this framework, managers get an end-to-end view of their innovation efforts. They can pinpoint their weakest links and tailor innovation best practices appropriately to strengthen those links. Companies typically succumb to one of three broad "weakest-link" scenarios. They are idea poor, conversion poor, or diffusion poor. The article looks at the ways smart companies - including Intuit, P&G, Sara Lee, Shell, and Siemens- modify the best innovation practices and apply them to address those organizations' individual needs and flaws. The authors warn that adopting the chain-based view of innovation requires new measures of what can be delivered by each link in the chain. The approach also entails new roles for employees "external scouts" and "internal evangelists," for example. Indeed, in their search for new hires, companies should seek out those candidates who can help address particular weaknesses in the innovation value chain.

Entities:  

Mesh:

Year:  2007        PMID: 17580654

Source DB:  PubMed          Journal:  Harv Bus Rev        ISSN: 0017-8012


  8 in total

1.  Combining communication technology utilization and organizational innovation: evidence from Canadian healthcare decision makers.

Authors:  Jalila Jbilou; Réjean Landry; Nabil Amara; Salaheddine El Adlouni
Journal:  J Med Syst       Date:  2009-08       Impact factor: 4.460

2.  Network analysis of surgical innovation: Measuring value and the virality of diffusion in robotic surgery.

Authors:  George Garas; Isabella Cingolani; Pietro Panzarasa; Ara Darzi; Thanos Athanasiou
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

3.  Assessing Regional Differences in Green Innovation Efficiency of Industrial Enterprises in China.

Authors:  Jun-Liang Du; Yong Liu; Wei-Xue Diao
Journal:  Int J Environ Res Public Health       Date:  2019-03-15       Impact factor: 3.390

4.  Developing an Open Innovation Attitude Assessment Framework for Organizations: Focusing on Open Innovation Role Perspective and Locus of Activity.

Authors:  YoungPyo Jun; Kilsun Kim
Journal:  Behav Sci (Basel)       Date:  2022-02-11

Review 5.  Factors contributing to innovation readiness in health care organizations: a scoping review.

Authors:  Monique W van den Hoed; Ramona Backhaus; Erica de Vries; Jan P H Hamers; Ramon Daniëls
Journal:  BMC Health Serv Res       Date:  2022-08-05       Impact factor: 2.908

6.  The innovation value chain of patents: Breakthrough in the patent commercialization trap in Chinese universities.

Authors:  Hong Gong; Libing Nie; Yuyao Peng; Shan Peng; Yushan Liu
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

Review 7.  Extension and Advisory Organizations on the Road to the Digitalization of Animal Farming: An Organizational Learning Perspective.

Authors:  Chrysanthi Charatsari; Evagelos D Lioutas; Marcello De Rosa; Afroditi Papadaki-Klavdianou
Journal:  Animals (Basel)       Date:  2020-11-06       Impact factor: 2.752

8.  Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics.

Authors:  Rajesh Krishna
Journal:  Clin Transl Sci       Date:  2020-10-16       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.